1-4 of 4
Mangeng Cheng
Close
Sort by
Journal Articles

The enzymatic activity of 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase/IMP cyclohydrolase is enhanced by NPM-ALK: new insights in ALK-mediated pathogenesis and the treatment of ALCL

Francesco E. Boccalatte, Claudia Voena, Chiara Riganti, Amalia Bosia, Lucia D'Amico, Ludovica Riera, Mangeng Cheng, Bruce Ruggeri, Ole N. Jensen, Valerie L. Goss, Kimberly Lee, Julie Nardone, John Rush, Roberto D. Polakiewicz, Michael J. Comb, Roberto Chiarle, Giorgio Inghirami
Journal: Blood
Blood (2009) 113 (12): 2776–2790.
https://doi.org/10.1182/blood-2008-06-161018
Published: 2009
Includes: Supplemental data
Journal Articles

NPM-ALK Mutants in Kinase Domain Exhibit Altered Kinase Activity and Various Sensitivity to ALK Inhibitors.

Lihui Lu, Arup Ghose, Matt Quail, Bruce Ruggeri, Mangeng Cheng
Journal: Blood
Blood (2008) 112 (11): 1603.
https://doi.org/10.1182/blood.V112.11.1603.1603
Published: 2008
Journal Articles

Anaplastic lymphoma kinase activity is essential for the proliferation and survival of anaplastic large-cell lymphoma cells

Weihua Wan, Mark S. Albom, Lihui Lu, Matthew R. Quail, Nadine C. Becknell, Linda R. Weinberg, Dandu R. Reddy, Beverly P. Holskin, Thelma S. Angeles, Ted L. Underiner, Sheryl L. Meyer, Robert L. Hudkins, Bruce D. Dorsey, Mark A. Ator, Bruce A. Ruggeri, Mangeng Cheng
Journal: Blood
Blood (2006) 107 (4): 1617–1623.
https://doi.org/10.1182/blood-2005-08-3254
Published: 2006
Journal Articles

Identification and Characterization of an ALK Inhibitor That Attenuates the Proliferation and Survival of Anaplastic Large Cell Lymphoma-Derived Cell Lines and ALK Dependent Cell Lines.

Mangeng Cheng, Ph.D., Weihua Wan, Mark Albom, Linda Weinberg, Thelma Angeles, Ph.D., Matthew Quail, Lihui Lu, Ted Underiner, Ph.D., Robert Hudkins, Ph.D., Mark Ator, Ph.D., Bruce Ruggeri, Ph.D.
Journal: Blood
Blood (2004) 104 (11): 2485.
https://doi.org/10.1182/blood.V104.11.2485.2485
Published: 2004